- Home
- BLFS vs RCUS Comparison
BLFS vs RCUS Comparison
Compare BLFS & RCUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BLFS
- RCUS
- Stock Information
- Founded
- BLFS 1987
- RCUS 2015
- Country
- BLFS United States
- RCUS United States
- Employees
- BLFS N/A
- RCUS N/A
- Industry
- BLFS Medical/Dental Instruments
- RCUS Biotechnology: Pharmaceutical Preparations
- Sector
- BLFS Health Care
- RCUS Health Care
- Exchange
- BLFS Nasdaq
- RCUS Nasdaq
- Market Cap
- BLFS 1.1B
- RCUS 906.4M
- IPO Year
- BLFS 1989
- RCUS 2018
- Fundamental
- Price
- BLFS $21.22
- RCUS $8.63
- Analyst Decision
- BLFS Strong Buy
- RCUS Buy
- Analyst Count
- BLFS 7
- RCUS 10
- Target Price
- BLFS $30.57
- RCUS $23.75
- AVG Volume (30 Days)
- BLFS 583.9K
- RCUS 1.2M
- Earning Date
- BLFS 08-07-2025
- RCUS 08-07-2025
- Dividend Yield
- BLFS N/A
- RCUS N/A
- EPS Growth
- BLFS N/A
- RCUS N/A
- EPS
- BLFS N/A
- RCUS N/A
- Revenue
- BLFS $87,762,000.00
- RCUS $141,000,000.00
- Revenue This Year
- BLFS $21.21
- RCUS N/A
- Revenue Next Year
- BLFS $17.58
- RCUS $28.73
- P/E Ratio
- BLFS N/A
- RCUS N/A
- Revenue Growth
- BLFS 34.80
- RCUS N/A
- 52 Week Low
- BLFS $18.70
- RCUS $6.50
- 52 Week High
- BLFS $29.55
- RCUS $18.98
- Technical
- Relative Strength Index (RSI)
- BLFS 41.52
- RCUS 44.17
- Support Level
- BLFS $21.76
- RCUS $8.75
- Resistance Level
- BLFS $22.76
- RCUS $9.35
- Average True Range (ATR)
- BLFS 1.14
- RCUS 0.62
- MACD
- BLFS -0.11
- RCUS -0.15
- Stochastic Oscillator
- BLFS 22.41
- RCUS 13.14
About BLFS BioLife Solutions Inc.
BioLife Solutions Inc is a life sciences company that develops, manufactures, and markets bioproduction products and services that are designed to improve quality and de-risk biologic manufacturing, distribution, and transportation in the cell and gene therapy ("CGT") industry. The company provides solutions such as Cell Processing, Cold Chain, and Thawing. The company generates the majority of its revenue from Cell Processing through the biopreservation product "CryoStor". Geographically the company generates the majority of its revenue from the United States.
About RCUS Arcus Biosciences Inc.
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.